Role of *Pneumocystis jirovecii* in patients with different pulmonary underlying condition using a nested-PCR

Lucía Martínez Lamas\(^1\) Maria Teresa Pérez Rodríguez\(^2\) Isabel Álvarez Álvarez\(^1\) María Emilia Bouza Soage\(^1\) María del Pilar Figueroa Lamas\(^1\) Maximiliano Álvarez Fernández\(^1\)

Microbiology Service. Hospital Meixoeiro. EOXI Vigo

Internal Medicin Service. Hospital Meixoeiro. EOXI Vigo

ABSTRACT

Introduction. The prevalence of *Pneumocystis jirovecii* colonization and its role in pulmonary disease remains unclear. PCR methods have shown an improved sensitivity in the detection of this fungus. It has been suggested that the PCR results be combined with another test such as IFA to create a diagnostic algorithm.

Material and methods. A multiplex nested-PCR procedure with a 16S rRNA gene as the internal amplification control was evaluated to determine the role of *P. jirovecii* in pulmonary disease.

Results. A 20% of the 199 bronchoalveolar lavage samples were PCR-positive, 13.5% samples were PCR-inhibited, and the rate of *Pneumocystis*-colonisation was 6.4%. The sensitivity, specificity, positive predictive value and negative predictive value of the nested-PCR were 100%, 93%, 70% and 100%, respectively. The sensitivity of the nested-PCR was higher than the current "gold standard" immunofluorescence assay (IFA) (p< 0.0001). PCR-negative and PCR-positive patients did not show any clinical or radiological differences in the medical variables studied.

Conclusion. PCR could help the diagnosis of *Pneumocystis* pulmonary disease given the high negative predictive value of the technique. *P. jirovecii* DNA can frequently be detected in healthy population, so the analysis of the patient medical history is critical to make the correct clinical decision.

Keywords: *Pneumocystis jirovecii*; nested-PCR; internal control; colonisation; pulmonary disease.

Papel de *Pneumocystis jirovecii* en pacientes con diferente patología pulmonar de base usando una PCR anidada

RESUMEN

Introducción. La prevalencia de la colonización por *Pneumocystis jirovecii* y su papel en la enfermedad pulmonar sigue sin estar clara. Los métodos de PCR han demostrado una sensibilidad mejorada en la detección de este hongo. Se ha sugerido que los resultados de PCR se combinen con otra prueba como IFA para crear un algoritmo de diagnóstico.

Material y métodos. Se evaluó una PCR múltiple anidada con el gen 16S rRNA como el control interno de amplificación para determinar el rol de *P. jirovecii* en enfermedad pulmonar.

Resultados. Un 20% de las 199 muestras de lavado broncoalveolar fueron positivas para PCR, 13,5% muestras fueron inhibidas por PCR, y la tasa de colonización por *Pneumocystis* fue de 6,4%. La sensibilidad, especificidad, valor predictivo positivo y valor predictivo negativo de la PCR fueron del 100%, 93%, 70% y 100%, respectivamente. La sensibilidad de la PCR fue mayor que el ensayo de inmunofluorescencia “gold-standard” (IFA) actual (p <0,0001). Los pacientes PCR-negativos y PCR-positivos no mostraron diferencias clínicas o radiológicas en las variables médicas estudiadas.

Conclusion. La PCR podría ayudar al diagnóstico de la enfermedad pulmonar por *Pneumocystis* dado el alto valor predictivo negativo de la técnica. El ADN de *P. jirovecii* se puede detectar con frecuencia en poblaciones sanas, por lo que el análisis del historial médico del paciente es fundamental para tomar la decisión clínica correcta.

Palabras clave: *Pneumocystis jirovecii*; PCR anidada; control interno; colonización; enfermedad pulmonar.
INTRODUCTION

Pneumocystis jirovecii is an opportunistic fungal pathogen that causes pneumonia (PJP) in immunocompromised hosts. Over the past decade, despite the decreased number of PJP cases among HIV-infected patients, PJP has become a serious problem in immunodeficient patients with other immunosuppressive conditions [1, 2]. P. jirovecii has a global distribution; most people have serologic evidence of infection during early childhood [3, 4], and normal healthy individuals can carry this fungus. The colonisation may develop into PJP if there is a worsening of the underlying disease and the patient does not receive appropriate prophylaxis [2, 5, 6]. However, the prevalence of P. jirovecii infection without disease remains unclear and complicates the interpretation of positive results becoming the clinical diagnosis of PJP into a challenging question.

The detection of the fungus in the laboratory by direct microscopic immunofluorescent staining of respiratory smears and tissue specimens has long been considered the major diagnostic tool and the current “gold standard”. The development of PCR technology with increased sensitivity allowed the detection of subclinical infections and colonisations [7-9]. These new approaches are especially important for non-HIV immunocompromised patients where the diagnosis is more difficult [10]. Currently, molecular detection is superior to microscopic evaluation [11, 12].

PCR assays vary significantly in their detection technology, turnaround time, type of clinical sample and capacity to yield a quantitative versus qualitative result [8, 13-20]. Simple DNA extraction and nested PCR in bronchoalveolar lavage specimens has been shown to be a sensitive test [6], which may be performed in clinical laboratories [21], with similar or even better sensitivity than real-time PCR [22]. Nevertheless, bronchoalveolar lavage (BAL) samples may contain inhibitors of the PCR reaction. The use of an internal control (IC) can identify inhibitory substances and monitor the PCR reaction [23].

The objectives of this work were to determine the role of Pneumocystis jirovecii in the pulmonary disease and to evaluate a simple multiplex nested-PCR in bronchoalveolar samples to detect P. jirovecii.

MATERIAL AND METHODS

From April 2013 to April 2014, 199 BAL samples sent to the laboratory for the detection of any infectious agents from 197 patients at the 1250-tertiary bed University Hospital (CHUVI) were collected.

Sample preparation for staining. BAL samples were mixed V/V with Sputasol (Oxoid) and mixed vigorously for 5 min. Samples were centrifuged at 3000 g for 10 min, and the pellets were resuspended 1/10 in 0.9% NaCl. The resuspended pellet was used to prepare smears. An immunofluorescence assay (IFA) was performed with a fluorescein isothiocyanate-conjugated monoclonal antibody to P. jirovecii following the manufacturer's instructions (MONOFLUO™ Pneumocystis jirovecii IFA Test Kit, Bio-Rad, Laboratories, USA).

Sample preparation for DNA extraction. One ml of BAL samples were aliquoted in 200 µl each and were stored at -20°C until they were studied. DNA was extracted from stored BAL samples using an InstaGene Matrix kit (Bio-Rad Laboratories, USA) according to the manufacturer's recommendations.

The nested-PCR protocol for amplification of mtLSUrRNA in P. jirovecii was performed as previously described.

| Primers sequences and thermocycling nested-PCR conditions. |
|-------------------------------------------------------------|
| **Reaction** | **Target** | **Primer name** | **Primer sequences** | **Cycling conditions** |
|----------------|-----------|-----------------|---------------------|----------------------|
| **Primary amplification** | mtLSUrRNA | pAZ102-E | 5’-GATGGCTGTTTCCAAGCCA-3’ | 94°C 10 min |
| | | pAZ102-H | 5’-GTGTACGTGCAAAAGTACTC-3’ | 40 cycles |
| | | U1 | 5’-CCAGCAGCCCGAGTAATCG-3’ | 50°C 1 min |
| | 16sRNA | U2 | 5’-ATCGG(C/T)TACCTTGTTACG-3’ | 72°C 2 min |
| **Secondary amplification** | mtLSUrRNA | pAZ102-X | 5’-GTGAAATACAAGACTGGAG-3’ | 94°C 5 min |
| | | pAZ102-Y | 5’-TCATCTAATATAATGATGGAGC-3’ | 45 cycles |
| | | | 94°C 20sec |
| | | | 50°C 20sec |
| | | | 72°C 20sec |
| | | | 72°C 10 min |

Table 1

Rev Esp Quimioter 2018;31(4): 336-343
by Wakefield et al.[13]. The external primers pAZ102-E and pAZ102-H to mtLSUrRNA P. jirovecii gene amplification were used in the first amplification round which produced a 346 bp amplicon, being included in the same reaction as an internal control 16s rRNA gene amplification primers (U1 and U2), which produced a 996 bp product [24]. The internal primers pAZ102-X and pAZ102-Y were used in a second round to amplify a 260 bp fragment.

Each PCR reaction contained 5 µL of the extraction product, 12.5 µL QIAGEN Multiplex PCR MasterMix and 0.2 µM concentration of each primer in a total volume of 25 µL [QIAGEN Multiplex PCR kit,Qiagen, Hilden, Germany]; 5 µL of the first PCR product was used as the DNA template for the second PCR reaction. The PCR products were analysed by electrophoresis on 1% agarose gel stained with RedSafe TM Nucleic Acid Staining Solution (iNtRON Biotechnology Inc., Sungnam, Kyungki-Do, Republic of Korea) (table 1).

External controls, contamination prevention and validation of the nested-PCR product. During each PCR, a positive control (a BAL fluid sample from a patient with PJP, P. jirovecii positive immunofluorescence assay) and ultra-pure water as the negative control were used. Amplification of the 16s RNA was performed to confirm successful DNA extraction and the absence of PCR inhibitions. To avoid contamination, all steps (master mix preparation, DNA extraction, amplification, and addition of the PCR product) were performed in separate areas. To validate the usefulness of the primers U1/U2 to identify oropharyngeal bacteria by PCR that usually contaminate the BAL samples, the following bacteria were studied: Streptococcus mitis ATCC 49456, Streptococcus oralis ATCC 35037, Streptococcus dysgalactiae subsp equisimilis ATCC 10009, Corynebacterium striatum ATCC 7094, Hemophilus parainfluenzae ATCC 9796 and Neisseria cinerea ATCC 14685, getting a 996 bp product in all of them. The nested-PCR product was purified using a QIAquik PCR purification Kit (Qiagen, Hilden, Germany) and sequenced with the forward primer pAZ102-X. A BLAST search was performed to verify the PCR-amplicon result.

Clinical and microbiological data collection. Demographic and clinical data including: age, sex, haematological malignancies, solid tumours, transplant recipients (bone marrow or solid organ), immunosuppressive therapy, tobacco smoke exposure, inflammatory lung disease, HIV infection, anti-PJP prophylaxis or treatment, clinical symptoms, season of the year and other organisms identified in the specimen. All samples were studied according to the procedures, serological studies and molecular studies for difficult to culture bacteria and viruses were performed on request by the clinician [25].

Colonisation or Pneumocystis infection. Patients with a negative staining result who were PCR-positive were classified as colonised or infected based on a medical chart review. Colonisation was defined in cases involving a patient without symptoms, no previous infection or treatment for PJP, no radiological abnormalities and favourable clinical outcome without specific treatment or symptoms attributed to another basic pathology. Pneumocystis infection (true-PJP) was defined in the setting of symptoms (fever or low grade fever, cough, dyspnea, weight loss) and compatible radiography or CT scan [26], provided that no other infectious agent or immune-allergic aetiology were identified.

Statistical analysis. Analysis was performed using SPSS version 20.0 (Chicago, IL, USA). All clinical variables were compared between the PCR-positive and PCR-negative groups. Continuous variables were compared using Student’s t-test, and categorical data were compared using the Chi-squared test. A two-tailed p value <0.05 was considered statistically significant.

Sensitivity, specificity and positive predictive value (PPV) and negative predictive value (NPV) of IFA and PCR were calculated. Positive-PCR results in patients with pneumonia were considered true-positive. False positive was considered the positive-PCR results in colonized patients. To determine the predictive values, we assumed a PJP prevalence of 20%, which is considered the median rate of colonisation in immunocompetent adults [27].

RESULTS

Nested-PCR results. For the 199 BAL specimens tested by nested-PCR, 35 (20.3%) were positive, 137 (68.8%) were negative and 27 (13.5%) were PCR-inhibited.

There was an initial inhibition of the PCR reaction in 47 samples, but the inhibition problems were resolved in 20 of them, with a second DNA extraction of the original specimens. This produced a total of 27 samples that were definitely considered as PCR-inhibited.

Comparison of classic staining/nested-PCR. Only 6 of the PCR-positive samples were positive based on IFA, and no negative PCR results with positive microscopy results were found.

Based on the criteria established in the materials and methods section, we estimated the sensitivity and specificity of each technique: IFA sensitivity and specificity was 25% (IC 95%: 0.08-0.42) and 100% (IC 95%: 0.97-1), respectively, and the nested-PCR sensitivity and specificity was 100% (IC95%: 0.85-1) and 93% (IC 95%: 0.88-0.97), respectively. There was a significant difference in sensitivity between PCR and IFA (P<0.0001). The PPV of the technique was 70% (IC95%: 0.5-0.9), and the NPV was 100%.

A good correlation between the IFA and PCR results was found in HIV-positive patients (2/2), but PCR detected more possible PJP patients among the non-HIV immunocompromised groups.

Characteristics of the patients. The mean age of the 170 patients was 61 ± 14 years, 105 (62%) were male. The most common underlying diseases were haematologic malignancies or solid tumours (35%); only 11 patients were HIV positive (6.5%), 88 (51.8%) had chronic lung disease (COPD, asthma, pneumoconiosis, or interstitial lung disease). Active or previous exposure to tobacco was identified in 50% of the patients and
43.5% of the patients received immunosuppressive therapy including corticosteroids or chemotherapeutic agents. Seventeen percent of patients were treated or received prophylactic therapy for PJP.

PJP was diagnosed in 24 patients, and *P. jirovecii*-colonisation was diagnosed in 11 patients on basis of the criteria described in the material and methods. Table 2 summarises the clinical data from *P. jirovecii* PCR-positive patients. Direct flu-

---

### Table 2: Clinical data of positive-PCR patients

| Age | Sex | Underlying disease                              | Clinical presentation | Immunosuppressive therapy | Tobacco* exposure | Pneumocystis prophylaxis | Radiological signs | Sampling season | Colonisation/PJP |
|-----|-----|-----------------------------------------------|-----------------------|----------------------------|------------------|--------------------------|-------------------|----------------|-----------------|
| 62  | Male| Crohn’s disease                              | Asymptomatic          | Yes                        | Ex               | No                       | Infiltrate        | Spring         | Colonisation    |
| 71  | Female| Chronic lymphocytic leukaemia B               | Dyspnoea, cough, fever| Yes                        | No               | No                       | Infiltrate        | Spring         | Pneumonia       |
| 44  | Female| Bronchial asthma                              | Asthma exacerbation   | Yes                        | No               | No                       | Infiltrate        | Spring         | Pneumonia       |
| 64  | Female| Microscopic polyangiitis                      | Cough, fever          | No                         | Ex               | Yes                      | Normal            | Spring         | Pneumonia       |
| 39  | Female| Breast cancer                                 | Cough, dyspnea        | Yes                        | No               | No                       | Infiltrate        | Spring         | Pneumonia       |
| 68  | Male| Hypersensitivity pneumonitis                  | Asymptomatic          | No                         | Yes              | No                       | Normal            | Spring         | Colonisation    |
| 46  | Male| Silicosis                                     | Asymptomatic          | No                         | No               | No                       | Infiltrate        | Spring         | Colonisation    |
| 70  | Male| Colon cancer                                  | Dyspnoea, cough, fever| Yes                        | Ex               | No                       | Consolidation     | Summer         | Pneumonia       |
| 69  | Female| COPD                                          | Cough, fever          | Yes                        | Yes              | No                       | Infiltrate        | Summer         | Pneumonia       |
| 61  | Male| Silicosis                                     | Dyspnoea, cough       | No                         | Ex               | No                       | Infiltrate        | Summer         | Pneumonia       |
| 33  | Male| HIV                                           | Dyspnoea, cough       | No                         | No               | No                       | Infiltrate        | Summer         | Pneumonia       |
| 53  | Male| Chest chondrosarcoma                          | Dyspnoea, cough, fever| Yes                        | No               | No                       | Infiltrate        | Summer         | Pneumonia       |
| 64  | Female| Peritoneal pseudomyxoma                       | Dyspnoea, fever       | No                         | No               | No                       | Infiltrate        | Autumn         | Pneumonia       |
| 55  | Male| Bronchial asthma                              | Asymptomatic          | Yes                        | No               | No                       | Normal            | Autumn         | Pneumonia       |
| 73  | Male| Pulmonary fibrosis                            | Asymptomatic          | No                         | Ex               | No                       | Infiltrate        | Autumn         | Colonisation    |
| 64  | Male| ILD                                           | Asymptomatic          | Yes                        | No               | No                       | Infiltrate        | Autumn         | Colonisation    |
| 56  | Female| ILD                                           | Dyspnoea              | Yes                        | Ex               | No                       | Infiltrate        | Autumn         | Pneumonia       |
| 60  | Male| Silicosis                                     | Asymptomatic          | No                         | Yes              | No                       | No                | Autumn         | Colonisation    |
| 63  | Female| Chronic bronchitis                            | Asymptomatic          | No                         | Yes              | No                       | Infiltrate        | Autumn         | Colonisation    |
| 52  | Female| Hypersensitivity pneumonitis                  | Asymptomatic          | No                         | Yes              | No                       | Infiltrate        | Autumn         | Colonisation    |
| 75  | Female| Common variable immunodeficiency              | Dyspnoea, weight loss | Yes                        | No               | No                       | Infiltrate        | Autumn         | Pneumonia       |
| 53  | Male| Lung cancer                                   | Cough, fever, chest pain| Yes                       | Yes              | No                       | Infiltrate        | Autumn         | Pneumonia       |
| 63  | Male| Myelofibrosis                                 | Fever                 | Yes                        | Yes              | Yes                      | Infiltrate        | Winter         | Pneumonia       |
| 79  | Female| Bronchiectasis                                | Dyspnoea, cough, fever| No                         | No               | No                       | Infiltrate        | Winter         | Pneumonia       |
| 66  | Female| Breast cancer                                 | Fever, cough          | No                         | No               | No                       | Infiltrate        | Winter         | Pneumonia       |
| 53  | Male| Silicosis                                     | Asymptomatic          | No                         | Ex               | No                       | Consolidation     | Winter         | Colonisation    |
| 64  | Female| Bronchiectasis                                | Cough, low grade fever| No                         | Yes              | No                       | Nodule            | Winter         | Pneumonia       |
| 73  | Male| Acute pneumonia                               | Dyspnoea, cough, fever| No                         | Ex               | No                       | Nodule            | Winter         | Pneumonia       |
| 81  | Male| Lung abscess                                  | Cough, weight loss    | No                         | No               | No                       | Infiltrate        | Winter         | Colonisation    |
| 84  | Male| No disease                                    | Dyspnoea              | No                         | Yes              | No                       | Infiltrate        | Winter         | Pneumocystis pneumonia |
| 74  | Male| Ureter cancer and leukaemia                   | Cough, fever          | Yes                        | No               | No                       | Infiltrate        | Winter         | Pneumonia       |
| 73  | Female| Pulmonary fibrosis                            | Cough, fever          | Yes                        | Yes              | No                       | Infiltrate        | Winter         | Colonisation    |
| 37  | Female| No disease                                    | Cough, fever          | No                         | Yes              | No                       | Infiltrate        | Winter         | Pneumonia       |
| 57  | Female| Common variable immunodeficiency              | Cough, fever          | No                         | No               | No                       | Nodule            | Winter         | Pneumonia       |
| 49  | Male| HIV                                           | Dyspnoea, chest pain  | No                         | No               | No                       | Infiltrate        | Spring         | Pneumonia       |

*Ex: previous exposure to tobacco. ILD: Interstitial lung disease. COPD: chronic obstructive pulmonary disease. PJP: Pneumocystis jirovecii pneumonia*
Role of *Pneumocystis jirovecii* in patients with different pulmonary underlying condition using a nested-PCR

L. Martínez Lamas, et al.

Rev Esp Quimioter 2018;31(4): 336-343

340

gram-negative bacilli (n=7) were the most common isolated microorganisms, followed by *Enterobacteriaceae* spp. (n=5), *Haemophilus* spp. (n=5) and *A. fumigatus* (n=5). Microbiological results of the culture positive samples are summarised in Table 4.

**Clinical outcome.** IFA and PCR positive patients were treated for PJP. Three patients of the 35 PCR-positive patients died, the cause of death could not be attributable to PJP.

**DISCUSSION**

PJP is an opportunistic infection of increasing importance in non-HIV patients. In this study, only 2/35 (5.3%) of the PCR-positive patients were HIV-infected. It is well acknowledged that the diagnosis of PJP is particularly difficult in non-HIV patients, who can develop rapidly progressive PJP even with low fungus loads. In addition, in non-HIV patients, false negative results from tinctorial methods are more common [8, 9].

In most studies that compared microscopy with PCR methods for PJP diagnosis, PCR exhibited superior sensitivity for organism detection in patients with chronic lung disease and/or those on steroid treatment [3, 28, 29]. A recent me-

**Comparisons of clinical and radiological results between PCR-positive and PCR-negative patients.** The clinical features of the PCR-positive and PCR-negative patients are shown in Table 3. The PCR-positive results were more likely in females and in patients with prophylaxis, although there was no statistical significance. Nodules, consolidations and normal X-ray findings were also more common than infiltrates in PCR-negative patients. A diagnosis of an underlying lung disease was significantly associated with a negative PCR result. Other clinical conditions were not associated with a positive result for *P. jirovecii*.

**Microbiological results.** Eight (22.8%) of the 35 PCR-positive samples and 35 (25.5%) of the PCR-negative samples were positive for other pathogens. In the PCR-positive samples, the most commonly isolated microorganisms were *Staphylococcus aureus* (n=2), *Aspergillus fumigatus* (n=2) and *Haemophilus* spp. (n=2). In the PCR-negative samples, non-fermenting gram-negative bacilli (n=7) were the most common isolated microorganisms, followed by *Enterobacteriaceae* spp. (n=5), *Haemophilus* spp. (n=5) and *A. fumigatus* (n=5). Microbiological results of the culture positive samples are summarised in Table 4.

**Table 3** Comparisons of the clinical features PCR+ and PCR- patients.

|                        | PCR-positive (n=35) | PCR-negative (n=137) | p-value |
|------------------------|---------------------|----------------------|---------|
| Age, years             | 62 ± 13             | 61 ± 14              | 0.954   |
| Sex, Female            | 15 (42.8%)          | 49 (35.7%)           | 0.279   |
| Underlying disease     |                     |                      |         |
| Solid tumor            | 6 (17.1%)           | 21 (15.3%)           | 0.42    |
| Haematological malignancy | 4 (11.4%)        | 28 (21.1%)           |         |
| Immunosuppressive disease | 5 (14.3%)        | 19 (13.9%)           | 0.949   |
| Inflammatory lung disease (COPD/Asthma) | 11 (31.4%) | 77 (56.2%) | 0.0015 |
| HIV infection          | 2 (5.7%)            | 9 (6.5%)             | 0.726   |
| Organ transplantation  | 3 (8.5%)            | 16 (11.7%)           | 0.601   |
| Corticosteroids        | 14 (40%)            | 60 (4.4%)            | 0.68    |
| Tobacco exposure       |                     |                      |         |
| Active                 | 10 (28.6%)          | 34 (24.8%)           | 0.89    |
| Previous exposure to tobacco | 10 (28.6%)       | 32 (23.4%)           |         |
| Anti- PcP prophylaxis  | 3 (8.5%)            | 27 (19.7%)           | 0.12    |
| Positive microbiology culture results | 8 (22.8%) | 35 (25.5%) | 0.74 |
| X-ray findings         |                     |                      |         |
| Nodules                | 4 (11.4%)           | 25 (18.2%)           |         |
| Infiltrates            | 25 (71.4%)          | 70 (51.1%)           | 0.142   |
| Consolidations         | 3 (8.6%)            | 30 (21.9%)           |         |
| Normal                 | 3 (8.6%)            | 12 (8.8%)            |         |

**Comparisons of clinical and radiological results between PCR-positive and PCR-negative patients.** The clinical features of the PCR-positive and PCR-negative patients are shown in Table 3. The PCR-positive results were more likely in females and in patients with prophylaxis, although there was no statistical significance. Nodules, consolidations and normal X-ray findings were also more common than infiltrates in PCR-negative patients. A diagnosis of an underlying lung disease was significantly associated with a negative PCR result. Other clinical conditions were not associated with a positive result for *P. jirovecii*.
Role of *Pneumocystis jirovecii* in patients with different pulmonary underlying condition using a nested-PCR

L. Martínez Lamas, et al.
Rev Esp Quimioter 2018;31(4): 336-343

Recent studies in Europe showed that 31.8% of the patients with positive PCR results have a history of PJP or will develop PJP [29]. Surprisingly, in this study, the laboratory test to detect *P. jirovecii* was requested in less than 50% of patients, and half of the unrequested PCR-positive samples were from patients who were at risk of developing PJP.

The actual prevalence of *P. jirovecii* colonisation or subclinical infection in immunocompetent patients remains unclear. The results of the current study show a low rate of colonisation of 6.4%. Nevertheless, similar studies reported differences in the rate of colonisation. Recent studies have shown a *P. jirovecii* colonisation prevalence from 2.6% to 55% [27, 28]. The differences in the prevalence rate could be due to the respiratory sample used (BAL vs. sputum), differences in the studied patients, such as underlying disease and comorbidities or differences in the recognition of a positive case given the absence of universally accepted criteria to establish the diagnosis for PJP. On the other hand, recent studies have shown that colonised-patients with low loads could be candidates for *P. jirovecii* prophylaxis [34]. Obviously, the detection of a *P. jirovecii* infection has a direct therapeutic impact on the choice of appropriate antimicrobial therapy. Understanding the role of *P. jirovecii* colonisation in patients with underlying pulmonary or systemic disease may help identify patients at risk of developing PJP [35].

Calderón et al. showed that *P. jirovecii* carriage could be involved in the progression of COPD by means of the capacity of *P. jirovecii* during very early stages of the infection to induce, in animal models, alveolar macrophage activation, pro-inflammatory interleukin elevation, and changes in pulmonary surfactant [36]. In the present study, 10% of the COPD patients were PCR positive for *P. jirovecii*. Recent studies in Europe found rates of carriage in patients with chronic diseases between 6 and 40% [37, 38]. However, the association between high rates of *P. jirovecii* colonisation and chronic lung diseases is debatable. In the present study, there were more PCR-positive *P. jirovecii* patients in the group without any lung disease. This result could be related to the proportion of patients with malignancies that were higher in the group of patients without any pulmonary disease than in the group of patients with lung disease (48% versus 21%).

In the present study, it was not clear whether the presence of *P. jirovecii* with other pathogens contributed to the exacerbation of pneumonia, because of the low number of PJP in which another potential respiratory pathogen was isolated.

As far as we know, this is the first conventional-PCR method to detect *P. jirovecii* that uses a non-competitive bacterial internal amplification control (IAC) to reveal reaction failure due to the presence of inhibitory substances in the sample [39]. A current issue that limits the reliability and sensitivity of PCR is the degree of inhibition caused by inhibitory substances, especially in respiratory samples [40]. Many other PCR designed to detect *P. jirovecii* do not use IAC [13, 22], use nonbacterial IAC as exogenous internal commercial control or complex recombinant plasmids [7, 8, 15, 19]. Another strategy used was

| Table 4 | Microbiological isolates obtained from *P. jirovecii* PCR positive and negative samples. |
|---------|--------------------------------------------------------------------------------------|
| *P. jirovecii* PCR-positive | *P. jirovecii* PCR-negative |
| 8(37 (23%)* | 31/137 (23%)* |
| Staphylococcus aureus (n=2) | Aspergillus fumigatus (n=5) |
| Aspergillus fumigatus (n=2) | Haemophilus spp.* (n=5) |
| Haeomophilus spp. (n=2) | Pseudomonas spp.* (n=4) |
| Pseudomonas aeruginosa (n=1) | Escherichia coli (n=3) |
| Mycobacterium lentiflavum (n=1) | Candida spp.* (n=3) |
| Mycobacterium spp.* (n=3) | Streptococcus pneumoniae (n=3) |
| Other non-fermenting gram-negative* (n=3) |  |
| Staphylococcus aureus (n=2) | Seratia marcescens (n=2) |
| Brevundimonas diminuta (n=1) | Stenotrophomonas maltophilia (n=1) |

*Number of isolated microorganisms/total samples studied

*H. influenzae* (n=6); *H. parainfluenzae* (n=1)

*P. aeruginosa* (n=3); *P. fluorescens* (n=1)

*C. albicans* (n=3); *C. glabrata* (n=1)

*M. avium* (n=1); *M. lentiflavum* (n=1); *M. tuberculosis* (n=1)

*B. diminuta* (n=1); *B. cepacia* (n=1); *S. marcescens* (n=2); *S. maltophilia* (n=1).

ta-analysis showed a very high accuracy of PCR in BAL samples for the diagnosis of PJP in patients who are at risk and a pooled sensitivity of 98.3% and a specificity of 91.0% [9].

To select the targets and primers, Roberts et al. compared 9 PCR assays with different primers/targets and found that the most sensitive PCR technique should consider a mtLSUrRNA nested reaction with the potential of producing false positive results [30]. Consistent with published data [11, 29, 31] the mtLSUrRNA PCR method used in the present study detected 18 more *P. jirovecii*-infected and 11 more *P. jirovecii*-colonised patients than IFA, improving the sensitivity from 25% to 100% (p<0.01). IFA exhibited excellent specificity but lacked sensitivity, whereas PCR was much more sensitive and also detected colonised patients. In particular, all confirmed-PJP cases in the HIV patient group were detected by both methods, perhaps in relation to the higher fungus loads in the HIV-infected patients [32, 33]. However, nested PCR exhibited a higher sensitivity in the non HIV group.

The high NPV allowed excluding PJP. Nevertheless, clinical and radiological criteria are essential to interpret a PCR-positive result because the low PPV of this technique. Clinical diagnosis in conjunction with IFA and PCR are considered the cornerstones for PJP patient management [10]. Although *P. jirovecii* was not recognised as the main cause of disease, it might play an important role as a comorbidity cofactor in patients with a severe underlying disease [33]. Recent studies showed that 31.8% of the patients with positive PCR results have a history of PJP or will develop PJP [29]. Surprisingly, in this study, the laboratory test to detect *P. jirovecii* was requested in less than 50% of patients, and half of the unrequested PCR-positive samples were from patients who were at risk of developing PJP.

The actual prevalence of *P. jirovecii* colonisation or subclinical infection in immunocompetent patients remains unclear. The results of the current study show a low rate of colonisation of 6.4%. Nevertheless, similar studies reported differences in the rate of colonisation. Recent studies have shown a *P. jirovecii* colonisation prevalence from 2.6% to 55% [27, 28]. The differences in the prevalence rate could be due to the respiratory sample used (BAL vs. sputum), differences in the studied patients, such as underlying disease and comorbidities or differences in the recognition of a positive case given the absence of universally accepted criteria to establish the diagnosis for PJP. On the other hand, recent studies have shown that colonised-patients with low loads could be candidates for *P. jirovecii* prophylaxis [34]. Obviously, the detection of a *P. jirovecii* infection has a direct therapeutic impact on the choice of appropriate antimicrobial therapy. Understanding the role of *P. jirovecii* colonisation in patients with underlying pulmonary or systemic disease may help identify patients at risk of developing PJP [35].

Calderón et al. showed that *P. jirovecii* carriage could be involved in the progression of COPD by means of the capacity of *P. jirovecii* during very early stages of the infection to induce, in animal models, alveolar macrophage activation, pro-inflammatory interleukin elevation, and changes in pulmonary surfactant [36]. In the present study, 10% of the COPD patients were PCR positive for *P. jirovecii*. Recent studies in Europe found rates of carriage in patients with chronic diseases between 6 and 40% [37, 38]. However, the association between high rates of *P. jirovecii* colonisation and chronic lung diseases is debatable. In the present study, there were more PCR-positive *P. jirovecii* patients in the group without any lung disease. This result could be related to the proportion of patients with malignancies that were higher in the group of patients without any pulmonary disease than in the group of patients with lung disease (48% versus 21%).

In the present study, it was not clear whether the presence of *P. jirovecii* with other pathogens contributed to the exacerbation of pneumonia, because of the low number of PJP in which another potential respiratory pathogen was isolated.

As far as we know, this is the first conventional-PCR method to detect *P. jirovecii* that uses a non-competitive bacterial internal amplification control (IAC) to reveal reaction failure due to the presence of inhibitory substances in the sample [39]. A current issue that limits the reliability and sensitivity of PCR is the degree of inhibition caused by inhibitory substances, especially in respiratory samples [40]. Many other PCR designed to detect *P. jirovecii* do not use IAC [13, 22], use nonbacterial IAC as exogenous internal commercial control or complex recombinant plasmids [7, 8, 15, 19]. Another strategy used was
a second round of amplification with the addition of a DNA template to exclude the presence of inhibitors [18, 41]. In this work, 13.5% of samples were inhibited, demonstrating the clinical utility of IAC. Therefore, reporting false-negative results is avoided. Previous studies found inhibition rates of 23.7% [40]. As Döskaya et al. observed in retesting diluted samples [40] in 20 (11.6%) samples, inhibition problems were resolved with a second extraction round. Maybe the use of more efficient extraction systems would improve the results.

In conclusion, PJCP could be a serious problem for non-HIV patients, where the diagnosis by PCR has produced better results than traditional staining methods. The use of an internal control is necessary to ensure the reliability of the results, especially in samples with a high presence of PCR inhibitors such as respiratory samples. The PCR strategy used in this work has proven to be useful for routine clinical laboratories without access to more specialized diagnostic procedures, which are more expensive for the detection of *P. jirovecii* in respiratory samples. Our results could help in the understanding of the clinical features that are associated with colonisation or infection with this microorganism. However, more studies are needed to clarify these findings.

**CONFLICT OF INTEREST**

The authors declare that they have no conflicts of interest

**FUNDING**

None to declare

**REFERENCES**

1. Carmona EM, Limper AH. Update on the diagnosis and treatment of *Pneumocystis* pneumonia. Ther Adv Respir Dis 2011;5(1):41-59. PMID: 20736243
2. Monroy-Vaca EX, de Armas Y, Illnait-Zaragozi MT, et al. Genetic diversity of *Pneumocystis jirovecii* in colonized Cuban infants and toddlers. Infect Genet Evol 2014 Mar;22:60-6.PMID:24131883
3. Vargas SL, Hughes WT, Santolaya ME, et al. Search for primary infection by *Pneumocystis carinii* in a cohort of normal, healthy infants. Clin Infect Dis 2001;33(6):855-61.PMID:11247708
4. Respaldiza N, Medrano FJ, Medrano AC, et al. High seroprevalence of *Pneumocystis jirovecii* infection in Spanish children. Clin Microbiol Infect 2004;10(11):1029-31.PMID:15522012
5. Morris A, Norris KA. Colonization by *Pneumocystis jirovecii* and its role in disease. Clin Microbiol Rev 2012;25(2):297-317. PMID:22491773
6. Khodadadi H, Mirhendi H, Mohebali M, Kordbacheh P, Zarrinfar H, Makimura K. *Pneumocystis jirovecii* Colonization in Non-HIV-Infected Patients Based on Nester-PCR Detection in Bronchoalveolar Lavage Samples. Iran J Public Health 2013;42(3):298-305. PMID:23641407
7. Flori P, Bellete B, Durand F, et al. Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing *Pneumocystis jirovecii* pneumonia from bronchoalveolar lavage specimens. J Med Microbiol 2004;53(Pt 7):603-7. PMID:15184529
8. Alano A, Desoubeaux G, Sarfati C, et al. Real-time PCR assay-based strategy for differentiation between active *Pneumocystis jirovecii* pneumonia and colonization in immunocompromised patients. Clin Microbiol Infect 2011;17(10):1531-7.PMID:20946413
9. Fan LC, Lu HW, Cheng KB, Li HP, Xu JF. Evaluation of PCR in bronchoalveolar lavage fluid for diagnosis of *Pneumocystis jirovecii* pneumonia: a bivariate meta-analysis and systematic review. PLoS One 2013;8(9):e73099.PMID:24023814
10. Aznar ML, Perez-Fernandez N, Ruiz-Camps I, Martin-Gomez MT. Comparaison de las caracteristicas clinicas y pronosticas de la neumonia por *Pneumocystis jirovecii* en pacientes con y sin infeccion por el virus de la inmunodeficiencia humana. Enferm Infec Microbiol Clin 2014;32(8):545-7.PMID:24548547
11. Kaouech E, Kelle K, Anane S, et al. Pneumocystosa a *Pneumocystis jirovecii*: etude comparee de la PCR et des techniques de coloration. Pathol Biol (Paris) 2009;57(5):373-7.PMID:19038508
12. Arvanitis M, Anagnostou T, Fuchs BB, Caliendo AM, Mylonakis E. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev 2014;27(3):490-526. PMID:24982319
13. Wakefield AE, Guiver L, Miller RF, Hopkins JM. DNA amplification on induced sputum samples for diagnosis of *Pneumocystis carinii* pneumonia. Lancet 1991;337(8754):1378-9.PMID:1674765
14. Huang SN, Fischer SH, O’Shaughnessy E, Gill VJ, Masur H, Kovacs JA. Development of a PCR assay for diagnosis of *Pneumocystis carinii* pneumonia based on amplification of the multiplicity major surface glycoprotein gene family. Diagn Microbiol Infect Dis 1999;35(1):27-32.PMID:10529878
15. Larsen HH, Kovacs JA, Stock F, et al. Development of a rapid real-time PCR assay for quantitation of *Pneumocystis carinii* f. sp. carinii. J Clin Microbiol 2002;40(8):2989-93. PMID:12149363
16. Arcenas RC, Ulh JR, Buckwalter SP, et al. A real-time polymerase chain reaction assay for detection of *Pneumocystis jiroveci* from bronchoalveolar lavage fluid. Diagn Microbiol Infect Dis 2006;54(3):169-75. PMID:16423488
17. Rohner P, Jacomo V, Studer R, Schrenzel J, Graf JD. Detection of *Pneumocystis jirovecii* by two staining methods and two quantitative PCR assays. Infection 2009;37(3):261-5.PMID:19148577
18. Tia T, Putapornpit C, Kosuvin R, Kongpolprom N, Kawkitinarong K, Jongwutivis S. A highly sensitive novel PCR assay for detection of *Pneumocystis jirovecii* DNA in bronchoalveolar lavage specimens from immunocompromised patients. Clin Microbiol Infect 2012;18(6):598-603.PMID:2191479
19. Dalanke AH, Hofko M, Zorn M, Zimmermann S. Evaluation of the fully automated BD MAX Cdiff and Xpert C. difficile assays for direct detection of *Clostridium difficile* in stool specimens. J Clin Microbiol 2013;51(6):1906-8.PMID:23678059
20. Wilson JW, Limper AH, Gys TE, Karre T, Wengenack NL, Birnicker MJ. *Pneumocystis jirovecii* testing by real-time polymerase chain reac-
tion and direct examination among immunocompetent and immu-
nosuppressed patient groups and correlation to disease specificity. Diagn Microbiol Infect Dis 2011;69(2):145-52.PMID:21251557

21. Rabodonirina M, Raffenot D, Cotte L, et al. Rapid detection of Pneumocystis carinii in bronchoalveolar lavage specimens from human immunodeficiency virus-infected patients: use of a simple DNA extraction procedure and nested PCR. J Clin Microbiol 1997;35(11):2748-51.PMID:9350726

22. Alvarez-Martinez MJ, Miro JM, Valls ME, et al. Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimens. Diagn Microbiol Infect Dis 2006;56(2):153-60.PMID:16678378

23. Rosenstraus M, Wang Z, Chang SY, DeBonville D, Spadoro JP. An internal control for routine diagnostic PCR: design, properties, and effect on clinical performance. J Clin Microbiol 1998;36(1):191-7. PMID:9413945

24. Lu JJ, Perng CL, Lee SY, Wan CC. Use of PCR with universal primers and restriction endonuclease digestions for detection and identification of common bacterial pathogens in cerebrospinal fluid. J Clin Microbiol 2000;38(6):2076-80.PMID:10834956

25. Cacho Calvo JB MPM, Oliver Palomo A, Puig de la Bellacasa J. Diagnóstico microbiológico de las infecciones del tracto respiratorio inferior. Procedimiento 25. Sociedad Española de Enfermedades Infecciosas y Microbiología clínica 2007.

26. Calderon EJ, Gutierrez-Rivero S, Durand-Joly I, Dei-Cas E. Pneumocystis jiroveci pneumonia in humans: diagnosis and treatment. Expert Rev Anti Infect Ther 2010;8(6):683-701.PMID:20521896

27. Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of pneumocystis colonization. J Infect Dis 2008;197(1):10-7. PMID:18171279

28. Medrano FJ, Montes-Cano M, Conde M, et al. Pneumocystis jirovecii in general population. Emerg Infect Dis 2005;11(2):245-50.PMID:15752442

29. Lu Y, Ling G, Qiang C, et al. PCR diagnosis of Pneumocystis pneumonia: a bivariate meta-analysis. J Clin Microbiol 2011;49(12):4361-3. PMID:22012008

30. Robberts FJ, Liebowitz LD, Chalkley LJ. Polymerase chain reaction detection of Pneumocystis jiroveci: evaluation of 9 assays. Diagn Microbiol Infect Dis 2007;58(4):385-92.PMID:17689766

31. Gupta R, Mirdha BR, Guleria R, et al. Diagnostic significance of nested polymerase chain reaction for sensitive detection of Pneumocystis jiroveci in respiratory clinical specimens. Diagn Microbiol Infect Dis 2009;64(4):381-8.PMID:19631091

32. Jarboui MA, Sellami A, Sellami H, et al. Molecular diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients. Mycoses 2010;53(4):319-33.PMID:19469333

33. Robert-Gangneux F, Belaz S, Revest M, et al. Diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients by real-time PCR: a 4-year prospective study. J Clin Microbiol 2014;52(9):3370-6.PMID:25009050

34. Maillet M, Maubon D, Brion JP, et al. Pneumocystis jiroveci (Pj) quantitative PCR to differentiate Pj pneumonia from Pj colonization in immunocompromised patients. Eur J Clin Microbiol Infect Dis 2014 Mar;33(3):331-6.PMID:23990137

35. Gutierrez S, Respaldiza N, Campano E, Martinez-Risquez MT, Calderon EJ, De La Horra C. Pneumocystis jirovecii colonization in chronic pulmonary disease. Parasite 2011 May;18(2):121-6. PMID:21678787

36. Calderon EJ, Rivero L, Respaldiza N, et al. Systemic inflammation in patients with chronic obstructive pulmonary disease who are colonized with Pneumocystis jiroveci. Clin Infect Dis 2007;45(2):e17-9. PMID:17578770

37. Probst M, Ries H, Schmidt-Wieland T, Serr A. Detection of Pneumocystis carinii DNA in patients with chronic lung diseases. Eur J Clin Microbiol Infect Dis 2000;19(8):644-5. PMID:11014833

38. Calderon E, de la Horra C, Medrano FJ, et al. Pneumocystis jiroveci isolates with dihydropteroate synthase mutations in patients with chronic bronchitis. Eur J Clin Microbiol Infect Dis 2004;23(7):545-9. PMID:15175932

39. Hoorfar J, Malorny B, Abdulmawjood A, Cook N, Wagner M, Fach P. Practical considerations in design of internal amplification controls for diagnostic PCR assays. J Clin Microbiol 2009;47(1):1863-8. PMID:15131141

40. Doskaya M, Caner A, Degirmenci A, et al. Degree and frequency of inhibition in a routine real-time PCR detecting Pneumocystis jirovecii DNA for the diagnosis of Pneumocystis pneumonia in Turkey. J Med Microbiol 2011;60(Pt 7):937-44. PMID:21459903

41. Jiancheng W, Minjun H, Yi-jun A, et al. Screening Pneumocystis carinii pneumonia in non-HIV-infected immunocompromised patients using polymerase chain reaction. Diagn Microbiol Infect Dis 2009;64(4):396-401.PMID:19631093